Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Tekla Life Sciences InvestorsNYSE: HQL
Other Non-Cash Items · Q2 FY2026 · quarter ended Mar 2026
Other non-cash items turns negative
Q2 FY2026 other non-cash items was -$66.7M, compared with $46.26M a year earlier.
Context
- Other non-cash items amounted to 101.5% of revenue in FY2025.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (87.71M) USD
- Year-over-year change
- —
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (87.71M) | — |
| FY2023 | 2023-09-30 | (22.35M) | -21468.6% |
| FY2022 | 2022-09-30 | 104.6K | +262.1% |
| FY2021 | 2021-09-30 | (64.53K) | +47.6% |
| FY2020 | 2020-09-30 | (123.05K) | — |
Other Non-Cash Items vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's FY2025 other non-cash items of $87.71M is the 6th largest of the 10 companies compared; the peer median is $11.67M.
- Other non-cash items amounts to 101.5% of revenue for HQL, versus a peer median of 92.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $271.32M | -23.6% | +17.9% | 1109.7% | |
| LTM Dec 2025 | $204.37M | +712.4% | +80.9% | 122.0% | |
| LTM Mar 2026 | $127.58M | +280.7% | — | 86.4% | |
| LTM Mar 2026 | $114.83M | +528.9% | -19.3% | 92.0% | |
| LTM Mar 2026 | $104.26M | -458.8% | -51.5% | 147.8% | |
| FY2025 | $87.71M | — | — | 101.5% | |
| FY2024 | $39.16M | -27.0% | -1.9% | 97.4% | |
| LTM Mar 2026 | $11.67M | -86.0% | +43.7% | 14.2% | |
| LTM Mar 2026 | $2.63M | -105.4% | — | 2.3% | |
| LTM Jun 2025 | $342.54K | -329.0% | +10.2% | 0.8% | |
| Peer median (excluding HQL) | $11.67M | -27.0% | +10.2% | 92.0% | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Sep 2020 | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | 123.05K | 64.53K | (104.6K) | 22.35M | 85.59M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 0 | 0 | 0 | 0 | (203.41K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 59.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 0 | 0 | 0 | 0 | (262.64K) |
| Other Non-Cash Items | (123.05K) | (64.53K) | 104.6K | (22.35M) | (87.71M) |
| Operating Cash Flow | 0 | 0 | 0 | 0 | (2.32M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (5) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (314.13M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 339.34M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 25.21M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (31.63M) |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 0 | 0 | 0 | (31.63M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 8.81M |
| Net Change in Cash | 0 | 990 | (545) | 32 | 75.54K |
| Free Cash Flow | 0 | 0 | 0 | 0 | (2.32M) |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.